If you have been diagnosed with chronic fatigue syndrome (aka myalgic encephalomyelitis or systemic exertion intolerance disease) or have debilitating and chronic fatigue, you may be eligible to participate in a treatment clinical trial that we are conducting at UAB in Birmingham, Alabama.
Benefits of the study:
-
- Participants get to try a new medication that may reduce their symptoms.
- Participants completing the study will receive $425.
- Participants will receive some blood tests and will be informed of the results.
Participant Requirements:
-
- Once a month, while the study is being conducted, participants must be able to come to a 2-hour visit at the University of Alabama in Birmingham.
- Participants must be able to participate for a period of 7 months.
- Participants must have been diagnosed with CFS (aka ME/SEID) or have experienced chronic, debilitating fatigue during the previous 12 months.
- Participants must not be on an opioid treatment for pain.
- Participants must be women who are 18-65 in age.
There may be other participant requirements not mentioned above.
About the Study:
The primary purpose of this study is to determine whether low-dose naltrexone affects the immune system function and symptoms of people who have chronic fatigue or chronic fatigue syndrome. The study is expected to last 7 months. In addition to the monthly visits to UAB, participants will need to take the drug or placebo daily and report symptoms on a electronic tablet we provide. This is a double-blind, placebo-controlled study. All participants will be given LDN treatment at some point of their study participation.
Contact our study director, Luke Parkitny by email, if you are interested in participating: ldnmecfs@gmail.com
If you are interested in participating in any of our other studies, please fill out this screener.
